Jan. 29, 2021 — An international team of researchers studying COVID-19 has made a startling and pivotal discovery: The virus appears to cause the body to make weapons to attack its own tissues.
The finding could unlock a number of COVID’s clinical mysteries. They include the puzzling collection of symptoms that can come with the infection; the persistence of symptoms in some people for months after they clear the virus, a phenomenon dubbed long COVID; and why some children and adults have a serious inflammatory syndrome, called MIS-C or MIS-A, after their infections.
“It suggests that the virus might be directly causing autoimmunity, which would be fascinating,” says lead study author Paul Utz, MD, who studies immunology and autoimmunity at Stanford University in Stanford, CA.
The study also opens the question of whether other viruses might also break the body’s tolerance to itself, setting people up for autoimmune diseases like multiple sclerosis, rheumatoid arthritis, and lupus later in life.
Utz says he and his team are next going to study flu patients to see if that virus might also cause this phenomenon.
“My prediction is that it isn’t going to be specific just to SARS-CoV-2. I’m willing to bet that we will find this with other respiratory viruses,” he says.
The study comes on the heels of a handful of smaller, detailed investigations that have come to similar conclusions.
The study included data from more than 300 patients from four hospitals: two in California, one in Pennsylvania, and another in Germany.
Researchers used blood tests to study their immune responses as their infections progressed. Researchers looked for autoantibodies — weapons of the immune system that go rogue and launch an attack against the body’s own tissues. They compared these autoantibodies to those found in people who were not infected with the virus that causes COVID.
As previous studies have found, autoantibodies were more common after COVID — 50% of people hospitalized for their infections had autoantibodies, compared to less than 15% of those who were healthy and uninfected.
Some people with autoantibodies had little change in them as their infections progressed. That suggests the autoantibodies were there to begin with, possibly allowing the infection to burn out of control in the body.
“Their body is set up to get bad COVID, and it’s probably caused by the autoantibodies,” Utz says.
But in others, about 20% of people who had them, the autoantibodies became more common as the infection progressed, suggesting they were directly related to the viral infection, instead of being a preexisting condition.
Some of these were antibodies that attack key components of the immune system’s weapons against the virus, like interferon. Interferons are proteins that help infected cells call for reinforcements and can also interfere with a virus’s ability to copy itself. Taking them out is a powerful evasive tactic, and previous studies have shown that people who are born with genes that cause them to have lower interferon function, or who make autoantibodies against these proteins, appear to be at higher risk for life-threatening COVID infections.
“It seems to give the virus a powerful advantage,” says study author, John Wherry, PhD, who directs the Institute for Immunology at the University of Pennsylvania.
“Now your immune system, instead of having a tiny little hill to climb, is staring at Mount Everest. That really is devious.”
In addition to those that counterpunch the immune system, some people in the study had autoantibodies against muscles and connective tissues that are seen in some rare disorders
Utz says they started the study after seeing COVID patients with strange collections of symptoms that looked more like autoimmune diseases than viral infections — skin rashes, joint pain, fatigue, aching muscles, brain swelling, dry eyes, blood that clots easily, and inflamed blood vessels.
“One thing that’s very important to note is that we don’t know if these patients are going to go on to develop autoimmune disease,” Utz says. “I think we’ll be able to answer that question in the next 6 to 12 months as we follow the long haulers and study their samples.”
Utz says it will be important to study autoantibodies in long haulers to see if they can identify exactly which ones seem to be at work in the condition. If you can catch them early, it might be possible to treat those at risk for enduring symptoms with drugs that suppress the immune system.
What this means, he says, is that COVID will be with us for a long, long time.
“We have to realize that there’s going to be long-term damage from this virus for the survivors. Not just the long haulers, but all the people who have lung damage and heart damage and everything else. We’re going to be studying this virus and it’s badness for decades,” Utz says.
BioRxiv, Jan. 29, 2021.
Paul Utz, MD, professor, immunology and rheumatology, Stanford University, Stanford, CA.
John Wherry, PhD, chair, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia.
© 2021 WebMD, LLC. All rights reserved.